Immucell (ICCC) Total Liabilities (2010 - 2026)

Immucell (ICCC) has reported Total Liabilities for 17 consecutive years, with $15.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 9.48% year-over-year to $15.3 million; the trailing twelve-month figure through Jun 2026 stood at $15.3 million (down 9.48% YoY), and the FY2025 full-year result was $15.5 million, down 11.97% from the prior year.
• Total Liabilities slipped to $15.3 million in Q2 2026 per ICCC's latest filing, from $15.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $18.8 million in Q4 2023 and bottomed at $13.4 million in Q2 2022.
• Historically, Total Liabilities has averaged $16.3 million across 5 years, with a median of $16.6 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities grew 29.93% in 2023, then declined 11.97% in 2025.
• Over 5 years, Total Liabilities stood at $14.5 million in 2022, then rose by 29.93% to $18.8 million in 2023, then declined by 6.55% to $17.6 million in 2024, then declined by 11.97% to $15.5 million in 2025, then slipped by 1.43% to $15.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $15.3 million, $15.5 million, and $15.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.